292 related articles for article (PubMed ID: 1374810)
1. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
[TBL] [Abstract][Full Text] [Related]
2. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
[TBL] [Abstract][Full Text] [Related]
3. Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.
Javaherian K; Langlois AJ; Montefiori DC; Kent KA; Ryan KA; Wyman PD; Stott J; Bolognesi DP; Murphey-Corb M; Larosa GJ
J Virol; 1994 Apr; 68(4):2624-31. PubMed ID: 7511176
[TBL] [Abstract][Full Text] [Related]
4. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
6. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
[TBL] [Abstract][Full Text] [Related]
7. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
[TBL] [Abstract][Full Text] [Related]
9. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.
Palker TJ; Muir AJ; Spragion DE; Staats HF; Langlois A; Montefiori DC
Virology; 1996 Oct; 224(2):415-26. PubMed ID: 8874502
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
[TBL] [Abstract][Full Text] [Related]
12. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
[TBL] [Abstract][Full Text] [Related]
13. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.
Spenlehauer C; Saragosti S; Fleury HJ; Kirn A; Aubertin AM; Moog C
J Virol; 1998 Dec; 72(12):9855-64. PubMed ID: 9811721
[TBL] [Abstract][Full Text] [Related]
14. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
[TBL] [Abstract][Full Text] [Related]
15. Hypervariable epitope constructs representing variability in envelope glycoprotein of SIV induce a broad humoral immune response in rabbits and rhesus macaques.
Meyer D; Anderson DE; Gardner MB; Torres JV
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):751-60. PubMed ID: 9643375
[TBL] [Abstract][Full Text] [Related]
16. Antigenic and immunogenic sites of HIV-2 glycoproteins.
Chiodi F; Björling E; Samuelsson A; Norrby E
Chem Immunol; 1993; 56():61-77. PubMed ID: 8452654
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
18. Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.
Zolla-Pazner S; Powell R; Yahyaei S; Williams C; Jiang X; Li W; Lu S; Wang S; Upadhyay C; Hioe CE; Totrov M; Kong X
J Virol; 2016 Dec; 90(24):10993-11006. PubMed ID: 27630234
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
[TBL] [Abstract][Full Text] [Related]
20. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses.
Kuwata T; Takaki K; Yoshimura K; Enomoto I; Wu F; Ourmanov I; Hirsch VM; Yokoyama M; Sato H; Matsushita S
J Virol; 2013 May; 87(10):5424-36. PubMed ID: 23468483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
